A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to <18 years) before initiating the PK study in younger cohort (6 to <12 years)
Epistemonikos ID: 87ff360f9246344ab80c47e8004c050a85086177
First added on: May 22, 2024